Compare RC & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RC | ALXO |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | 442 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 257.3M | 240.8M |
| IPO Year | N/A | 2020 |
| Metric | RC | ALXO |
|---|---|---|
| Price | $1.75 | $1.49 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $2.81 | ★ $3.50 |
| AVG Volume (30 Days) | 1.5M | ★ 1.5M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.16% | N/A |
| EPS Growth | N/A | ★ 26.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $67.36 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.50 | $0.41 |
| 52 Week High | $4.75 | $2.66 |
| Indicator | RC | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 51.25 | 41.31 |
| Support Level | $1.57 | $1.37 |
| Resistance Level | $1.88 | $1.59 |
| Average True Range (ATR) | 0.10 | 0.12 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 63.49 | 30.77 |
Ready Capital Corp is a real estate finance company that originates, acquires, finances, and services LMM loans, SBA loans, construction loans, USDA loans and, to a lesser extent, MBS collateralized mainly by LMM loans or other real estate-related investments. Its loans are used by businesses to purchase real estate used in their operations or by investors seeking to acquire multi-family, office, retail, mixed use or warehouse properties. It operates through two segments: LMM Commercial Real Estate, which originates LMM loans across the life-cycle of an LMM property including construction, bridge, stabilized and agency loan channels, and Small Business Lending, which acquires, originates and services owner-occupied loans guaranteed by the SBA and also originates and services USDA loans.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.